Learn About Primary Amebic Meningoencephalitis
Montefiore Weiler Hospital
Our primary research interest is in the biology, pathogenesis and immunology of Plasmodium falciparum. Patients infected with this parasite can be completely asymptomatic or develop severe disease resulting in death. The goal of our research has been to define the molecular mechanisms that underlie this variation in disease outcomes in P. falciparum. Toward this goal, we have developed a new pathogenesis model through the analysis of in vivo parasite biology and associated host factors using a whole genome and metabolomic approach. We have identified novel parasite biology when it resides in the human host and idnetified a putative mediator of coma in cerebral malaria. We also are studying adjunctive therapy to improve outcomes in severe malaria using the animal model. We carry out field based translational studies in cohorts infected with malaria in Africa and test hypothesis in the animal model of malaria. The long term goal is to identify parasite and host processes involved in disease to serve as targets for vaccine or chemotherapeutic development. Dr. Daily is rated as an Elite provider by MediFind in the treatment of Primary Amebic Meningoencephalitis. Her top areas of expertise are Primary Amebic Meningoencephalitis, Malaria, Togaviridae Disease, Severe Acute Respiratory Syndrome (SARS), and Leg or Foot Amputation.
Terrie Taylor is a primary care provider, practicing in Internal Medicine in East Lansing, Michigan. Dr. Taylor is rated as an Elite provider by MediFind in the treatment of Primary Amebic Meningoencephalitis. Her top areas of expertise are Primary Amebic Meningoencephalitis, Malaria, Sepsis, and Increased Intracranial Pressure.
Chandy John is a Pediatric Infectious Disease provider in Indianapolis, Indiana. Dr. John is rated as an Elite provider by MediFind in the treatment of Primary Amebic Meningoencephalitis. His top areas of expertise are Primary Amebic Meningoencephalitis, Malaria, Multisystem Inflammatory Syndrome in Children (MIS-C), and Bacterial Meningitis. Dr. John is currently accepting new patients.
Summary: The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are: * Determine the pharmacokinetic (PK) profile of a single dose of DON in children with CM * Determine if administration of a single intravenous dose o...
Summary: Background and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and deaths. In 2022, the World Health Organisation (WHO) recommended post-discharge malaria chemoprevention (PDMC) for childre...